KERX and AEZS have a phase 3 trial for colorectal cancer coming to a conclusion in first quarter of 2012. A successful outcome will multiply the values of the stocks many times. One analyst has over a twenty dollar target for KERX. The drug in trial is Perifosine. KERX owns North American rights, AEZS gets royalties on that and has ROW rights with partnerships in Japan, Middle East, and South Korea. Current share prices on both are suppressed. Success is not guaranteed, but the price is so low and the possible reward is great because a successful oral compound for this cancer is a ticket to a lofty valuation for both companies.